Search

EHA-Baltic Hematology Tutorial on Bleeding Disorders & Thrombosis

EHA IN COLLABORATION WITH BALTIC SOCIETIES CONCLUDE THE FIRST HYBRID TUTORIAL MEETING IN EHA HISTORY!

 

EHA-Baltic Hematology Tutorial on Bleeding Disorders & Thrombosis
August 28 – 30, 2020
Virtual & Riga, Latvia 

Meeting Chairs:

Prof S Eichinger (European Hematology Association)
Prof S Lejniece (Latvian Society of…

Read more

All-encompassing meeting on ALL highly rated by participants

Almost 200 delegates from over 30 countries benefitted from stimulating and excellent discussions about Acute Lymphoblastic Leukemia (ALL) at the EHA-SWG Scientific Meeting on New Molecular Insights and Innovative Management Approaches for Acute Lymphoblastic Leukemia on April 12-14, 2018 in…

Read more

Highlights of Past EHA (HOPE ) Asia 2021 - report

In the first weekend of September (September 3-4), EHA opened the virtual platform for HOPE Asia 2021.

Read more

What an EHA Kick-off Grant supports

Our EHA Kick-off Grant supports basic and translational lab-based research in hematology. Costs that can be supported by an EHA Kick-off Grant
Lab consumables. Max € 5,000 for equipment, if properly justified.

Read more

In memoriam Daniel Catovsky

Professor Daniel Catovsky MD DSc
19. 9. 1937 – 2. 12. 2022

Daniel Catovsky died peacefully in December at the age of 85 years.

Read more

HemaSphere Editorial Board

Editor-in-Chief
Jan Cools, Belgium
Deputy Editor-in-Chief
Claire Harrison, United Kingdom
Associate Editors
Jeroen Eikenboom, The Netherlands
Simone Ferrero (Italy)
Adele Fielding, United Kingdom
Simon Hallam, United Kingdom
Robert Hills, United Kingdom
Steffen Koschmieder, Germany
Marek Mraz (Czech Republic)
Paula Rodríguez Otero, Spain
Juerg Schwaller, Switzerland

Francesca Vinchi, USA
Scientific Editors
Charles de Bock, Australia
Stephen Hibbs, United…

Read more

Restoring Effective Anti-Tumor Response in Hodgkin Lymphoma with Nivolumab

Hodgkin Lymphoma typically affects young men and women in their 30s. Although it is highly curable with the current combination of chemo and radiation therapy, approximately 20% of patients will not be cured with first line regimens.

Read more